Learn how FreeStyle Libre 14 day system can help make CGM more accessible for more of your patients.
No fingerstick calibration
Factory-calibrated sensor delivers proven accuracy1 for 14 days with no need for fingerstick calibration or sensor coding.
Painless2 glucose readings
Provides patients with real-time glucose readings for insulin dosing without the need for fingersticks.*
The first and only 14 day personal continuous glucose monitoring (CGM) solution clinically proven to reduce time spent in hypoglycemia3,4
Discreet sensor is easy to apply and comfortable to wear, making it simple for patients to monitor their glucose levels.2
Clinically proven to be accurate, stable, and consistent with a MARD of 9.4%.1
Most commercially insured patients will pay between $40 and $75 per month for the FreeStyle Libre 14 day sensor.‡
New FreeStyle Libre 14 day system
2 sensors per month
Available soon at participating pharmacies§ with a new prescription.
* Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
† Based on the manufacturer’s list price of the FreeStyle Libre 14 day system. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
‡ Benefits for sensors apply to two 14-day sensors per month. Benefits for reader applies to one 14-day reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs, or residents of US territories and possessions, except Puerto Rico. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available with a valid prescription at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary.
§ Participating pharmacies are subject to change without notice.
References: 1. FreeStyle Libre 14 day User’s Manual. 2. Data on file. Abbott Diabetes Care. 3. Bolinder J, Antuna R, Geelhoed- Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked randomised controlled trial. Lancet. 2016;388(10057):2254-2263. 4. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73.
ADC-09181 Ver 1.0 08/18
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
Do you wish to leave this site?
Thank you for submitting your details. We will contact you as soon as possible.